Disruptiveinnovations in medicine are thriving all around the world, especially in universities and hospitals. However, the number of new drugs entering the development pipeline is dangerously drying up.
As a bridge between academic science and industrial development, 4P-Pharma accelerates innovation. It detects gem projects in order to bring better human health products for patients. Since 2014, 4P-Pharma has pre-evaluated more than 300 molecules, and carried out a technological due diligence on 18 of them.
Today, 4P-Pharma has incorporated two in clinical-stage asset-centric companies : 4Moving Biotech and 4Living Biotech. 4Moving Biotech focusing on 4P004, a long-term solution to treat Osteoarthritis (OA). Worldwide, 300 million people are affected, 15% of the adult population. 4Living Biotech, focusing on 4P021, a new treatment for patients with severe COVID-19.
4Moving Biotech (4P004) received the Seal of Excellence from the European Commission.
